Botswana pays equivalent of $15 a dose for Sinovac's 19 vaccine



GABORONE, July 30 (Reuters) - Botswana's health minister said on Friday that the government was paying the equivalent of $15 a dose for the COVID-19 vaccine developed by China's Sinovac Biotech and almost $29 a dose for U.S. company Moderna's shot.

African countries have struggled to procure enough vaccines in the global scramble for doses, with coverage secured through World Health Organization (WHO) and African Union (AU)-backed schemes so far falling short of the continent's needs.

Under pressure over a recent spike in COVID-19 infections, health minister Edwin Dikoloti revealed how much the diamond-rich southern African country was paying in bilateral deals with pharmaceutical companies Sinovac SVA.O , Moderna MRNA.O and India's Bharat Biotech.

Dikoloti said in an address to parliament that Botswana had signed agreements to pay $3 million for 200,000 doses of the Sinovac vaccine, $14.44 million for 500,000 doses of Moderna's vaccine, and $1.6 million for 100,000 doses from Bharat Biotech. The Bharat Biotech deal works out at $16 per shot.

The minister added that the COVAX facility co-led by the WHO had only delivered 82,000 doses despite an upfront payment the government had made as a self-financing participant, hoping to secure far more doses.

An AU arrangement is expected to deliver over 1.1 million doses of Johnson & Johnson's JNJ.N vaccine in the third and fourth quarters.

Botswana has currently only fully vaccinated around 124,000 of its 2.3 million population.

Apart from the shots it is paying for, the Indian government donated 30,000 doses of the COVISHIELD vaccine manufactured by the Serum Institute of India and China donated 200,000 doses of Sinovac's vaccine. Botswana is still in talks with Pfizer PFE.N about a possible 2 million dose deal, Dikoloti said.


Reporting by Brian Benza Writing by Alexander Winning

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示: 您的資金存在風險。杠杆商品可能不適合所有客戶。 請詳細閱讀我們的風險聲明